The results of clinical trials in Asian women and adults living with HIV were presented at the Asia-Pacific AIDS & Co-Infections Conference 2020
A post-hoc pooled analysis from three studies showed the effectiveness of switching to B / F / TAF from antiretroviral therapy based on an integrase strand transfer inhibitor (INSTI) or a boosted protease inhibitor (PI) with two baselines – Nucleotide reverse transcriptase inhibitor (NRTI) regimens among virologically suppressed Asian adults living with HIV. In the analysis, 100 percent of the 63 Asian adults who switched to B / F / TAF retained virologic suppression (defined as HIV-1 RNA
Similarly, an open, randomized phase 3 study in women with HIV who had been virologically suppressed (HIV-1 RNA
These results further demonstrate the well-established efficacy and safety profile of Biktarvy. No participant in B / F / TAF developed treatment-related resistance. The additional data further define the treatment regimen.
Biktarvy® (Bictegravir 50 mg / Emtricitabine 200 mg / Tenofovir alafenamide 25 mg; B / F / TAF) is approved in Hong Kong, Singapore, South Korea, Taiwan and Thailand as a single daily tablet (STR) for the treatment of HIV. 1 infection in adults. B / F / TAF is indicated for the treatment of HIV-1 infection in adults with no current or previous evidence of viral resistance to the integrase inhibitor class emtricitabine or tenofovir.
These were the details of the news Gileads Biktarvy supports virus suppression and tolerance in Asian HIV patients for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at de24.news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.